True Light Capital
淡明资本
True Light Capital (淡明资本) is an independent wholly-owned subsidiary of Singapore's Temasek, established to invest in high-quality opportunities in Greater China . It operates its sole office outside Singapore from Shanghai's Jing'an Kerry Centre . In early 2026, it co-led a nearly RMB 600 million Series C round in Chengdu-based biotech Zai Ling Bio alongside Qiming Venture Partners, with follow-on participation from Tencent Investment, BlueRun Ventures, and others , and also joined the $150 million Series B for macrocyclic peptide drug developer Syneron Bio .
AI-generated — may contain errors, please verify.
Coverage
5Y News | Syneron Bio Closes $150 Million Series B Round
Syneron Bio today announced the completion of its Series B funding round.
五源资本·New Forces Keep Coming｜5Y News Monthly
The big news from last month.
五源资本·5Y News | Zai Ling Bio Completes Nearly RMB 600 Million Series C Financing
The funding will go toward global clinical development, pipeline expansion, and technology platform upgrades.
五源资本·A Foreign PE Firm's Thirtieth Birthday Party
"Writing a New Chapter, Setting Sail for Distant Horizons"
暗涌Waves·
